Industry News

Unilife Corporation announced today that it has received a letter from The NASDAQ Stock Market LLC notifying the Company that it is not in compliance with NASDAQ Listing Rule 5250 (c) because it has not filed its Annual Report on Form 10- K for the period ended June 30, 2016 in a timely manner with the Securities and Exchange Commission. NASDAQ Listing Rule 5250 (c) requires listed companies to timely file all required periodic financial reports..."/>
Unilife Corporation Announces Receipt of Delinquency Letter from NASDAQ Relating to Fiscal 2016 Form 10-K
KaloBios Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced the filing with the U.S. Securities and Exchange Commission of the company’ s Forms 10- Q for the three months ended March 31, 2016, and for the three and six months ended June 30, 2016.. KaloBios is now current with its SEC periodic reporting requirements."/>
KaloBios Now Current on SEC Periodic Filings
Sunshine Heart, Inc. today announced that on September 21, 2016, it received a letter from the Nasdaq Listing Qualifications Staff indicating that the Company did not timely demonstrate compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company intends to request a hearing before the Nasdaq hearings panel to present its plan to demonstrate..."/>
Sunshine Heart Announces Receipt of Nasdaq Staff Determination; To Request Hearing
Allergan plc today announced the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA ® Cohesive breast implants, offering women undergoing reconstruction, augmentation or revision surgery a new breast shaping option that combines a high gel fill ratio and Allergan's highly cohesive gel 1,2 for a customized result. The new NATRELLE INSPIRA ® Cohesive line of breast implants is the newest..."/>
Allergan Announces FDA Approval of NATRELLE INSPIRA® Cohesive Breast Implants
AMN Healthcare Services, Inc. announced today that its subsidiary, AMN Healthcare, Inc., priced its previously announced private offering of senior notes due 2024 and increased the offering size from $300 million to $325 million. The Senior Notes will bear an interest rate of 5.125% per annum and will be issued at 100.00% of their face value. The Senior Notes will be guaranteed by the Company's affiliates that guarantee the Company's credit..."/>
AMN Healthcare Announces Pricing Of Senior Notes Offering
Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced that as previously disclosed in its Annual Report on Form 10- K for the year ended June 30, 2016, which was filed on September 19, 2016 with the Securities and Exchange Commission, the audited financial..."/>
Palatin Technologies Receives Audit Opinion with Going Concern Explanation
Ignyta, Inc., a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27, 2016, at 9:30 a.m. Eastern time in New York, NY, and will discuss Ignyta’ s Rx/Dx approach and review recent updates from ongoing clinical trials of the company’ s robust pipeline of molecularly targeted therapies."/>
Ignyta to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced the closing of its previously announced underwritten public offering of 6,152,500 shares of its common stock, including 802,500 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a..."/>
Aquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Endo International soared Friday after the drug maker named Paul V. Campanelli as president and CEO effective immediately. The company, with U.S. headquarters in Malvern, said that Rajiv De Silva has stepped down as chief executive officer and a board member. Endo shares were up 17.18 percent, or $3.48, to $23.74 at noon."/>
Endo names new CEO, stock surges [Philly.com]
Indivior, and MonoSol Rx conspired to block generic competitors for Suboxone by switching the drug from a tablet to a dissolving film."/>
Maryland among 36 states suing makers of heroin addiction treatment drug Suboxone for antitrust violations [The Baltimore Sun]
Universal American Corp.. Best has affirmed the Financial Strength Rating of B+ and the Long-Term ICR of“ bbb-” of American Progressive Life& Health Insurance Company of New York. Best has affirmed the FSR of B and the Long-Term ICR of“ bb+” of SelectCare of Texas, Inc.."/>
A.M. Best Withdraws Credit Ratings of Universal American Corp. and Its Subsidiaries
Achillion Pharmaceuticals, Inc. announced that updated interim results were presented today in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen..."/>
Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV
Veracyte, Inc. today announced new data suggesting the potential to enhance the performance of the Afirma Gene Expression Classifier in thyroid cancer diagnosis by combining the test's proven RNA expression-based capabilities with gene variant and fusion information– all on a single, robust RNA sequencing platform. Such enhancements could help to further reduce the number of patients who undergo unnecessary surgery..."/>
Veracyte Presents Data Demonstrating Potential to Enhance Afirma® Gene Expression Classifier Using an RNA Sequencing Platform
Celldex Therapeutics, Inc. announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in a fireside chat at the Leerink Partners Rare Disease& Immuno-Oncology Roundtable on Thursday, September 29, 2016 at 2:00 p.m. EDT in New York.. The live webcast will be available on the "Events& Presentations" page of the "Investors& Media" section of..."/>
Celldex Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable
Biostar Pharmaceuticals, Inc. has agreed to acquire all equity interest in China-based health product maker Xianyang Yongsheng Health Products Co., Ltd. for a cash payment and issuance of shares of Biostar's restricted common stock, the company said. Biostar said that the amount of the cash payment is to be determined following completion of the due diligence review of the target."/>
Biostar Pharmaceuticals to Acquire Chinese Health Product Maker Xianyang Yongsheng
Biocept, Inc., a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that Lyle Arnold, Ph.D., Chief Scientific Officer of Biocept, will present at two SelectBio conferences being held between September 26-30 in San Diego. Arnold's presentations will focus on Biocept's patented Target-Selector™..."/>
Biocept's Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences
Pulmatrix, Inc. today announced that a recent white paper, What is the future of inhalation delivery? ,by global research and consulting firm Envigo predicts rapid growth for drugs that are delivered to the lungs through inhalation. "The global market for inhalation drug delivery methodology alone is expected to reach US $48 bn by 2016," says the report."/>
Pulmatrix Highlights Recent Report Predicting Rapid Growth for Inhaled Drug Delivery Methods
Synergy Pharmaceuticals Inc. today announced the company will present at the OctoberINVESTfest Conference on Wednesday, September 28, 2016 at 11:30 a.m. Eastern Time at the New York Academy of Sciences in New York. A live webcast of the presentation will be accessible through the Investor Relations section of the company’ s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’ s website for 60 days following the conference."/>
Synergy Pharmaceuticals to Present at OctoberINVESTfest 2016
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has entered into an exclusive distribution agreement with Isla Lab LLC that includes both Puerto Rico and the U.S. Chembio recently announced that it had entered into an exclusive distribution agreement with Isla Lab Caribbean that included the 25 Caribbean nations. With today’ s announcement, Isla Lab becomes Chembio’ s..."/>
Chembio Expands Exclusive Distribution Agreements with Isla Lab to Include Puerto Rico and U.S. Virgin Islands
TG Therapeutics, Inc. today announced that Michael S. Weiss, the Company's Executive Chairman and Interim Chief Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference being held at the Sofitel Hotel in New York, NY. The presentation is scheduled to take place on Tuesday September 27, 2016 at 11:30am ET. A live webcast of this presentation will be available on the Events page, located within the Investors& Media section, of the..."/>
TG Therapeutics, Inc. to Present at the Ladenburg Thalmann 2016 Healthcare Conference
CytoSorbents Corporation, a critical care immunotherapy leader commercializing its flagship CytoSorb ® cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed an exclusive distribution agreement with Armaghan Salamat Kish Group to distribute CytoSorb ® for all critical care, cardiac surgery, and other hospital applications in..."/>
CytoSorbents Expands CytoSorb® into Iran with Partner Arsak

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology589 Articles
Consumer Discretionary545 Articles
Financials358 Articles
Industrials336 Articles
Health Care327 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.